Cumulatively, these studies reveal that DNMT3A mutations promote survival and chemotherapy resistance in cells from patients with T-ALL and identify BIRC5 as a specific genetic dependency of DNMT3A-mutant T-ALL cells. The gene discussed is BIRC5; the disease is acute lymphoblastic leukemia.